Raynaud's phenomenon and vascular disease in scleroderma

Area of Science:

• Vascular Biology
• Rheumatology
• Scleroderma Research

Background:

• Raynaud's phenomenon is the primary vascular manifestation in scleroderma.
• Current laboratory assessments for microvascular function lack sufficient specificity and sensitivity for individual patient diagnosis.
• Investigating the pathogenesis of Raynaud's phenomenon provides insight into early scleroderma stages.

Purpose of the Study:

• To explore the mechanisms underlying Raynaud's phenomenon in scleroderma.
• To highlight the role of endothelial dysfunction and vascular tone dysregulation.
• To identify potential therapeutic targets for vascular complications in scleroderma.

Main Methods:

• Clinical evaluation for Raynaud's phenomenon.
• Review of current literature on vascular and endothelial mechanisms in scleroderma.
• Analysis of factors contributing to microvascular thrombosis, including fibrinolysis and platelet aggregation.

Main Results:

• Clinical assessment remains the most reliable diagnostic method for Raynaud's phenomenon.
• Proposed mechanisms include dysregulated vascular tone, deficiency in vasodilatory neuropeptides, decreased fibrinolysis, and enhanced platelet aggregation.
• Endothelial injury markers are increasingly described, though the exact nature remains unclear.

Conclusions:

• Raynaud's phenomenon is a critical indicator of vascular disease in scleroderma.
• Further research into endothelial involvement and vascular tone dysregulation is crucial.
• New therapeutic agents, such as calcitonin gene-related peptide, offer promise for managing vascular spasm.